This article was originally published in The Gray Sheet
Firm, which will formally assume the name Maxxim Medical following shareholder approval at the company's March 4 meeting, is offering $50 mil. in convertible subordinated debentures due March 1, 2003. Estimated net proceeds of $47.9 mil. will be used "to finance potential future acquisitions and for general corporate purposes," Henley says in a Feb. 2 registration statement filed with the SEC. The firm notes that "no acquisitions or negotiations for any acquisitions are currently pending." Following the offering, which is being underwritten by Kemper Securities and Morgan Keegan & Company, Henley's long term debt will total $52.7 mil.
You may also be interested in...
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.